Immuron Limited ADR(IMRN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 5:20 PM ET (Korea 10/1 06:20)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.34 | Insider Own | - | Shs Outstand | 8.1M | Perf Week | -0.85% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 3.3M | Perf Month | 4.5% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 0.97% | Short Float | 3.56% | Perf Quarter | 6.42% |
| Income | -0.00B | P/S | 1.79 | EPS this Y | - | Inst Trans | 53.76% | Short Ratio | 0.06 | Perf Half Y | 49.72% |
| Sales | 0.01B | P/B | 1.21 | EPS next 5Y | - | ROA | -31.68% | Short Interest | 0.12M | Perf YTD | 52.13% |
| Book/sh | 0.96 | P/C | 1.5 | EPS past 3/5Y | 9.11% 21.57% | ROE | -38.31% | 52W High | -51.46% ($2.39) | Perf Year | -38.95% |
| Cash/sh | 0.77 | P/FCF | - | Sales past 3/5Y | 62.68% 116.97% | ROIC | -32.25% | 52W Low | 71.47% ($0.68) | Perf 3Y | -41.41% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 42.44% | Gross Margin | 64.54% | Volatility(W/M) | 6.15% 9.56% | Perf 5Y | -70.78% |
| Dividend TTM | - | EV/Sales | 0.6 | Sales Y/Y TTM | 10.41% | Oper. Margin | -61.63% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.98 | EPS Q/Q | 48.4% | Profit Margin | -47.78% | RSI (14) | 44.76 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.26 | Sales Q/Q | 18.7% | SMA20 | -12.5% ($1.33) | Beta | 1.1 | Target Price | $4 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -3.16% ($1.2) | Rel Volume | 0.04 | Prev Close | $1.19 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - 3.06% | SMA200 | 15.52% ($1) | Avg Volume(3M) | 2.07M | Price | $1.16 |
| IPO | 2017/3/2 | Option/Short | No/Yes | Trades | 281 | Volume | 81,745 | Change | -2.52% |
🦠 (Immuron) is a commercial- and clinical-stage biopharmaceutical micro-cap company headquartered in Melbourne, Australia. Its core product is Travelan®, an oral immunotherapy that prevents travelers' diarrhea, generating revenue through over-the-counter (OTC) and dietary-supplement channels in Australia and the United States, while the company simultaneously develops a clinical-stage antibody pipeline that includes IMM-529.
Over the past 1 year, roughly in the middle
51% below its 1-year high.
Traded less than usual That is 4% of its average volume.
IMRN has a sound balance sheet but weak earning power
Of every $100 in sales, $61.63 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $179. Peers typically go for $1,243.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -70.8%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.0%.
Tap to view numbers
It ranks #514 of 592 in the industry
Based on market cap of $9M.
FAQ
What kind of company is IMRN?
IMRN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMRN?
The market cap of IMRN is approximately $9M, ranking 5,509 within its sector.
What is the 52-week high and low for IMRN?
IMRN has recorded a 52-week high of $2.39 and a low of $0.68.
